Physician profile
Lisa B Burch
NPI 1932107943
$8,916.32
in general payments reported to CMS, 2019-2025
41 companies · $1,137 in 2025
The $1,137 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $896 · 2020: $1,309 · 2021: $1,337 · 2022: $1,099 · 2023: $1,645 · 2024: $1,492 · 2025: $1,137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,234 · Education: $40.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,234.01 |
| Education | $40.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,258.33 | 2019-2025 | Spravato, Xarelto |
| Astrazeneca Pharmaceuticals LP | $724.86 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $716.93 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $641.21 | 2022-2025 | |
| Novo Nordisk INC | $609.76 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $573.89 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $483.19 | 2019-2023 | Belsomra, Januvia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $443.33 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Abbvie INC. | $405.63 | 2021-2025 | Vraylar, Linzess, Viberzi |
| Bayer Healthcare Pharmaceuticals INC. | $368.10 | 2023-2025 | |
| Amgen INC. | $365.69 | 2019-2025 | Evenity, Prolia, Otezla |
| Allergan, INC. | $257.39 | 2019-2020 | |
| Glaxosmithkline, LLC. | $226.63 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $218.08 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $201.61 | 2019-2021 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Burch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.